UNSPSC 51363103: Amphenidone

This classification denotes a sedative and hypnotic with the molecular formula C11H10N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M61FM2VCSV, chemically known as 2(1h)-pyridone, 1-(m-aminophenyl)- but generally known as amphenidone, which bears US NIH Compound Identifier 8641. European Medicines Agency schedules Amphenidone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05484MIG.

UNSPSC 51363103 Amphenidone is a Commodity code that captures pharmaceutical products and related health-sector procurement, though recent state and local opportunities show the code being applied to naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply arrangements rather than amphenidone specifically. State and local governments are using this code to solicit naloxone and drug deactivation systems for community health initiatives, to explore direct contracting models with pharmaceutical manufacturers outside traditional pharmacy benefit manager arrangements, and to establish cooperative purchasing agreements for generic pharmaceuticals and over-the-counter products across multi-state and multi-jurisdiction networks. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances administering procurement on behalf of member state agencies and local government facilities (Minnesota Multistate Cooperative Purchasing Alliance).

Recent activity appears concentrated in Florida and Texas, with multi-state cooperative procurement reaching Oregon and other participating jurisdictions. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on vendor capabilities for implementing a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026 and awarded vendors effective July 1, 2026. The MMCAP procurement weighted price competitiveness at 75 percent of evaluation and imposed a 3 percent administrative fee on all contract purchases.